Report Description Table of Contents Therapeutic Robots Market: Reimbursement Expansion and High-Intensity Rehabilitation Shift Robotics from Pilot Use to Funded Care The Global Therapeutic Robots Market is independently estimated at USD 1.05 billion in 2025 and is projected to reach approximately USD 2.65 billion by 2032, expanding at a CAGR of 14.4% during 2026–2032. The therapeutic robots market operates through rehabilitation, physical medicine, assistive mobility, and structured supportive care. Its commercial scope includes institutional gait-training robots, upper-limb rehabilitation systems, personal powered exoskeletons, myoelectric orthoses, and socially assistive robots used in dementia, autism, paediatric, and long-term-care programs. Surgical robots, hospital logistics systems, pharmacy automation, telepresence-only devices, industrial exoskeletons, prosthetic limbs, and robotic drug-discovery laboratories are excluded because their buyers, regulatory pathways, reimbursement models, and demand units are materially different. Revenue is generated through capital-equipment sales, individual device purchases, rentals, subscriptions, therapist certification, extended warranties, maintenance, software, clinical-support services, and replacement components. A hospital robot is normally an episodic capital purchase followed by recurring support revenue. A personal exoskeleton or powered orthosis is sold for a specific patient after prescription, assessment, documentation, payer approval, fitting, and training. Commercial performance therefore depends less on total neurological prevalence than on the number of patients who reach funded rehabilitation settings and complete the eligibility process. Based on the global control estimate, rehabilitation robots represented approximately 54.4% of 2025 revenue, equivalent to about USD 571 million, followed by personal exoskeletons and powered orthoses at 19.0% or USD 200 million, socially assistive robots at 18.1% or USD 190 million, and myoelectric orthoses at 8.5% or approximately USD 89 million. 2.4 Billion-Person Rehabilitation Need Does Not Equal Robot Demand Approximately 2.4 billion people worldwide live with a condition that could benefit from rehabilitation. Global rehabilitation need increased by 63% between 1990 and 2019, rising from 1.48 billion to 2.41 billion people. WHO also estimates that about 86 million people require rehabilitation because of stroke. Access remains severely constrained in many lower-income markets, where rehabilitation workforce density can fall below ten skilled practitioners per one million people. This shortage supports the case for systems that increase treatment intensity, but it also limits robot adoption because equipment cannot be deployed effectively without trained clinicians, technical support, and rehabilitation infrastructure. Stroke creates one of the largest recurring patient inflows. More than 795,000 people experience a stroke each year in the United States, including around 610,000 first or new strokes. Mobility is reduced in more than half of stroke survivors aged 65 and older. Stroke supports demand for upper-limb, gait, balance, and assisted-mobility systems, but many survivors recover through conventional therapy, have mild impairment, cannot tolerate robotic training, or lack access to an equipped facility. Neurological rehabilitation accounted for an estimated 32.0% of the market in 2025, representing approximately USD 336 million, and is projected to reach about USD 888 million by 2032 at a CAGR of 14.9%. Its share is expected to increase to approximately 33.5% as stroke, spinal cord injury, neuromuscular disease, and multiple-sclerosis programs adopt higher-intensity robotic therapy. Spinal cord injury creates a smaller but higher-value personal-device opportunity. The 2025 U.S. estimate covers approximately 308,620 people living with traumatic spinal cord injury and about 18,421 new cases annually. Personal exoskeleton eligibility is much narrower because users may require adequate upper-body strength, cardiovascular stability, healthy bone density, sufficient cognition, safe standing tolerance, caregiver support, and the ability to complete extensive training. These restrictions explain why the installed base remains limited despite a sizeable prevalent population. Rehabilitation Facility Throughput Defines the Institutional Opportunity Medicare fee-for-service beneficiaries recorded approximately 435,000 inpatient rehabilitation facility stays across about 1,170 U.S. facilities in fiscal 2024. Medicare spending reached USD 11.0 billion, stays increased 7.6% from fiscal 2023, and the average stay lasted 12.4 days. Stroke represented 15.1% of stays, while other neurological conditions represented another 15.0%. Hospitals and rehabilitation centres represented an estimated 48.0% of therapeutic-robot revenue in 2025, equivalent to approximately USD 504 million. The segment is projected to reach about USD 1.19 billion by 2032 at a CAGR of 13.1%, although its share may moderate to 45.0% as home-use and community-based systems expand. Physical Rehabilitation Robots Remain the Commercial Centre Rehabilitation robots hold the strongest commercial position because they combine regulated medical use, high equipment value, measurable treatment sessions, and established hospital budgets. Lower-limb systems provide body-weight support, guided stepping, balance training, and repeated gait cycles. Upper-limb systems assist shoulder, elbow, wrist, hand, or finger movement and record force, range, speed, and task completion. The rehabilitation robots product category is projected to increase from approximately USD 571 million in 2025 to about USD 1.56 billion by 2032, expanding at a CAGR of 15.5%. Its market share is expected to rise from 54.4% to approximately 59.0% as institutional gait systems, upper-limb platforms, and neurologically focused rehabilitation robots secure wider clinical adoption. Gait and mobility training represented approximately 24.0% of 2025 market revenue, equivalent to USD 252 million, and is projected to reach around USD 676 million by 2032 at a CAGR of 15.1%. Its share is expected to increase to 25.5%, supported by stroke, spinal cord injury, multiple-sclerosis, and neuromuscular rehabilitation programs. Orthopedic rehabilitation accounted for an estimated 10.0% share and approximately USD 105 million in 2025. The application is projected to reach about USD 225 million by 2032 at an 11.5% CAGR, reflecting comparatively slower adoption in joint-replacement recovery, musculoskeletal injury, balance restoration, and post-operative mobility programs. Commercial value increasingly depends on treatment dose and utilisation data. Ekso reported that its rehabilitation repository contained approximately 350,000 patient sessions and more than 15 million step-level data points in 2025. Such datasets can support adaptive assistance, therapist reporting, product development, post-market evidence, and payer discussions. Their competitive value depends on data consistency, cybersecurity, interoperability, and the ability to connect device activity with functional outcomes. Reimbursement Turns Personal Robots into High-Value Medical Devices The United States created a significant payment pathway by classifying qualifying bilateral lower-limb exoskeletons under the Medicare brace benefit. CMS established a 2024 purchase fee schedule amount of USD 91,031.93 for HCPCS K1007. The payment amount creates a premium revenue opportunity, but payment still depends on correct coding, medical necessity, an eligible beneficiary, complete documentation, and successful claims processing. Personal exoskeletons and powered orthoses represented an estimated 19.0% of the market in 2025, generating approximately USD 200 million. The segment is projected to reach about USD 504 million by 2032 at a CAGR of 14.1%, retaining an estimated 19.0% share as reimbursement expansion is balanced by strict patient-eligibility requirements. Lifeward reported 778 ReWalk Personal units and 131 ReWalk Rehabilitation units placed by December 31, 2025. The disclosed personal installed base was almost six times the institutional ReWalk rehabilitation base, illustrating how patient-specific reimbursement can eventually create higher unit volume than facility sales. The figures remain manufacturer-specific and do not establish total market penetration. Home care settings represented approximately 18.0% of 2025 market revenue, equivalent to USD 189 million, and are projected to reach nearly USD 610 million by 2032 at a CAGR of 18.2%. Home care is expected to be the fastest-growing end-user segment, increasing its share to approximately 23.0% as lighter systems, connected controls, remote monitoring, and individual reimbursement expand. The FDA cleared the ReWalk 7 Personal Exoskeleton on March 12, 2025. Commercial access continued to improve afterward. Lifeward reported a first major commercial-insurer approval in April 2025, a Medicare appeal decision supporting medical necessity in June, and an initial Medicare Advantage payment processed in under 30 days in September. In February 2026, the company stated that Aetna had joined Humana and UnitedHealthcare in providing Medicare Advantage coverage for beneficiaries meeting medical-necessity criteria. Lifeward generated USD 22.0 million in revenue during 2025. Gross profit reached USD 8.4 million, producing a 38% gross margin compared with 32% in 2024. Research and development expenditure declined 30% to USD 3.2 million as development work on ReWalk 7 and another product program approached completion. These results show that regulatory clearance does not immediately ensure rapid growth: revenue decreased 14% in 2025 because weaker sales in other rehabilitation product lines offset exoskeleton progress. Upper-Limb Wearable Robotics Builds a Separate Reimbursement Market Upper-limb robotics is developing through patient-specific powered orthoses rather than large institutional platforms alone. Myomo’s MyoPro uses non-invasive sensors to detect neurological signals and assist a weakened or partially paralysed arm. The commercial model combines direct patient billing, orthotics and prosthetics providers, Veterans Affairs channels, rehabilitation-hospital referrals, and international distributors. Myoelectric orthoses represented an estimated 8.5% share of the global market in 2025, equivalent to approximately USD 89 million. The segment is projected to reach about USD 212 million by 2032 at a CAGR of 13.2%, with its share moderating to approximately 8.0% as institutional rehabilitation robots expand more rapidly. Myomo’s revenue increased 26% to USD 40.9 million in 2025, and the company delivered a record 750 MyoPro devices. Fourth-quarter revenue reached USD 11.4 million, while authorisations and orders reached a record 241. Recurring patient sources—including rehabilitation referrals, Veterans Affairs facilities, orthotics providers, and international channels—generated 42% of fourth-quarter revenue, up from 26% one year earlier. More than 150 rehabilitation hospitals and clinics had referred MyoPro candidates by May 2026. The company estimates that more than three million Americans live with chronic arm paralysis after stroke or another neurological injury and that approximately 250,000 additional patients each year continue to have arm or hand deficits after conventional rehabilitation. These are company estimates rather than national robot-eligibility counts, but they identify a substantial referral pool for wearable upper-limb systems. Upper-limb rehabilitation represented approximately 18.0% of the market in 2025, generating an estimated USD 189 million. Revenue is projected to reach about USD 464 million by 2032 at a CAGR of 13.7%, with the application accounting for approximately 17.5% of the forecast market. Specialty clinics accounted for an estimated 16.0% share and approximately USD 168 million in 2025. The end-user segment is projected to reach about USD 398 million by 2032 at a CAGR of 13.1%, supported by neurological, orthotic, spinal-injury, outpatient rehabilitation, and upper-limb referral networks. Myomo also reported expansion from approximately nine million covered Veterans Affairs lives in 2024 toward as many as 158 million covered lives after its announced payer arrangements are implemented. CMS raised the 2026 allowable payment for the MyoPro G, which accounts for more than 90% of company units, by 2% to USD 68,801. Payer denials remain commercially significant, particularly within Medicare Advantage, making authorisation rates and appeal capability major determinants of revenue conversion. Installed Bases Show Where Adoption Has Moved Beyond Pilots CYBERDYNE reported 536 Medical HAL lower-limb units in operation worldwide in June 2025, including research units, with 103 used for treatment in Japanese hospitals. It also reported 703 HAL single-joint units, 362 lower-limb wellbeing or living-support units, and 1,056 lumbar wellbeing units. These product categories have different medical and wellness classifications, but the figures demonstrate a broader installed ecosystem supporting rentals, clinical services, maintenance, and home programs. Academic and research institutes represented approximately 8.0% of market revenue in 2025, equivalent to USD 84 million. The segment is projected to reach about USD 186 million by 2032 at a CAGR of 12.0%, with its share moderating to 7.0% as commercially funded hospital and home-care deployments expand. Malaysia offers one of the clearest examples of government-backed scale. CYBERDYNE’s agreement with the national social-security organisation PERKESO covered 50 HAL sets comprising 65 units, under a contract worth up to approximately USD 4.6 million over five years. By June 2026, 182 HAL units were operating across 15 Malaysian facilities. The new national centre can accommodate up to 700 patients simultaneously and approximately 3,000 annually. Centralised reimbursement and procurement created multi-site deployment that would have been difficult to achieve through individual hospital sales. Wandercraft reported Atalante X deployments in more than 100 hospitals and rehabilitation centres. By June 2025, approximately 2,500 users had taken more than 14 million steps using the company’s technology. Atalante X had been evaluated in more than 20 studies. The company secured USD 75 million in equity and debt financing in 2025 to support institutional expansion and development of Eve, its self-balancing personal exoskeleton. Social Robots Address Large Care Burdens but Remain Selectively Funded Approximately 57 million people were living with dementia globally in 2021, with nearly ten million new cases annually. Dementia cost the global economy an estimated USD 1.3 trillion in 2019. Informal care accounted for about half of that cost, with family members and other carers providing an average of five hours of care and supervision per day. These figures create demand for technologies that support engagement and structured activity, but companion robots do not replace supervision or clinical care. Socially assistive robots represented an estimated 18.1% of the global market in 2025, equivalent to approximately USD 190 million. Revenue is projected to reach about USD 371 million by 2032 at a CAGR of 10.0%, with the share moderating to approximately 14.0% because fragmented reimbursement limits growth relative to physical rehabilitation systems. Dementia and elderly care accounted for an estimated 10.0% of market revenue in 2025, or approximately USD 105 million. The application is projected to reach about USD 252 million by 2032 at a CAGR of 13.3%, supported by ageing populations, dementia-care costs, workforce shortages, and demand for non-pharmacological engagement. A 2025 review included 15 randomised studies covering 705 people with dementia, with 12 studies entering meta-analysis. Robot interventions reduced agitation with a standardised mean difference of −0.36 and reduced anxiety by a weighted mean difference of −1.93. Improvements in cognition, quality of life, sleep, and physical activity were not consistent. Most studies involved only 22–175 participants and lasted six weeks to three months, limiting routine reimbursement arguments. A separate meta-analysis of older adults combined 42 effect sizes from 19 studies involving 1,083 participants to evaluate loneliness. The evidence supports continued investigation in nursing homes and independent-living settings, but differences in intervention design and study quality keep purchasing concentrated in targeted care programs rather than standard insurance coverage. Long-term-care facilities represented approximately 10.0% of 2025 market revenue, equivalent to USD 105 million, and are projected to reach about USD 265 million by 2032 at a CAGR of 14.1%. The segment is expected to retain an approximately 10.0% share as dementia-care programs expand but continue to depend on facility budgets and public funding. Autism and paediatric care form another emerging segment. CDC identified autism in about one in 31 eight-year-old children across 16 U.S. monitoring communities in 2022. Nearly 40% of identified children with a documented intelligence score also had intellectual disability. A meta-analysis of socially assistive robots used during needle procedures found lower anxiety and fewer distressed avoidance behaviours, although the evidence was rated as low certainty. These findings support use as an adjunct in selected paediatric settings, not as an independent treatment platform. Autism and paediatric support accounted for an estimated 6.0% share and approximately USD 63 million in 2025. The application is projected to reach about USD 146 million by 2032 at a CAGR of 12.7%, representing approximately 5.5% of forecast revenue as evidence development continues ahead of routine reimbursement. Regional Growth Follows Different Funding and Procurement Models North America held an estimated 42.5% share of the therapeutic robots market in 2025, representing approximately USD 446 million. The regional market is projected to reach about USD 1.07 billion by 2032 at a CAGR of 13.4%, with its share moderating to 40.5% as Asia-Pacific adoption accelerates. The United States provides the clearest patient-specific revenue route through the USD 91,031.93 Medicare amount for bilateral lower-limb exoskeletons and the USD 68,801 2026 allowable payment for the MyoPro G. It also has about 1,170 inpatient rehabilitation facilities serving 435,000 fee-for-service stays, making hospitals and rehabilitation centres the region’s principal institutional buyers. Europe represented an estimated 28.0% share and approximately USD 294 million in 2025. Revenue is projected to reach about USD 716 million by 2032 at a CAGR of 13.5%, with the region accounting for approximately 27.0% of forecast market value. Europe combines established rehabilitation capacity with fragmented reimbursement. In Germany, defined personal-exoskeleton reimbursement processes covered access pathways involving approximately 45% of the country’s 70 million statutory-health-insurance population, equivalent to around 31.5 million covered lives. Covered lives are not eligible users, and individual claims remain subject to approval. Asia-Pacific represented approximately 23.0% of the global market in 2025, equivalent to USD 242 million. The region is projected to reach approximately USD 702 million by 2032 at the fastest regional CAGR of 16.5%, increasing its share to about 26.5%. Asia-Pacific demonstrates stronger public-procurement potential. Malaysia’s HAL contract was valued at up to USD 4.6 million for 50 sets comprising 65 units over five years, while 182 HAL units were operating across 15 facilities by June 2026. Japan had 103 Medical HAL lower-limb systems operating in hospital treatment settings. LAMEA represented an estimated 6.5% share and approximately USD 68 million in 2025. The regional market is projected to reach about USD 159 million by 2032 at a CAGR of 12.8%, accounting for approximately 6.0% of forecast revenue as limited rehabilitation infrastructure constrains faster deployment. Commercial Outlook Through 2032 Institutional growth will depend on utilisation rather than demonstration placements. Personal-device growth will depend on the conversion of coding decisions into consistent payer approvals. Social robots will need larger comparative studies and defined institutional protocols before purchasing becomes routine. The most attractive revenue pools are high-throughput neurological rehabilitation centres, reimbursed personal-exoskeleton candidates, powered upper-limb orthosis users, national rehabilitation programs, and long-term-care systems with funded social-robot interventions. Suppliers that combine regulatory clearance, patient selection, payer navigation, therapist training, high system uptime, outcome reporting, and recurring service infrastructure will capture more commercial value than companies relying mainly on robotic novelty. The final segment model places rehabilitation robots at USD 571 million in 2025 and USD 1.56 billion by 2032, personal exoskeletons and powered orthoses at USD 200 million and USD 504 million, myoelectric orthoses at USD 89 million and USD 212 million, and socially assistive robots at USD 190 million and USD 371 million. Across applications, neurological rehabilitation and gait and mobility training are expected to remain the largest revenue pools, while home care settings and Asia-Pacific are projected to record the fastest end-user and regional growth. Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.05 Billion Revenue Forecast in 2032 USD 2.65 Billion Overall Growth Rate CAGR of 14.4% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) By Product Type Rehabilitation Robots; Personal Exoskeletons & Powered Orthoses; Myoelectric Orthoses; Socially Assistive Robots By Application Neurological Rehabilitation; Gait & Mobility Training; Upper-Limb Rehabilitation; Orthopedic Rehabilitation; Dementia & Elderly Care; Autism & Pediatric Support By End User Hospitals & Rehabilitation Centers; Home Care Settings; Specialty Clinics; Long-Term Care Facilities; Academic & Research Institutes By Geography North America; Europe; Asia-Pacific; Latin America; Middle East & Africa Market Drivers – Rising Rehabilitation Demand Growing global rehabilitation requirements due to stroke, spinal cord injuries, neurological disorders, ageing populations, and mobility impairments are increasing demand for robotic-assisted therapy solutions. Market Drivers – Expansion of Reimbursement Pathways Medicare coverage, payer approvals, and healthcare reimbursement frameworks are improving commercial access for personal exoskeletons, powered orthoses, and advanced rehabilitation systems. Market Drivers – Shift Toward High-Intensity Rehabilitation Hospitals and rehabilitation centers are adopting robotic platforms to deliver repetitive, data-driven, and personalized therapy while improving treatment efficiency and patient monitoring. Market Drivers – Growth of Home-Based Rehabilitation Lightweight robotic systems, remote monitoring capabilities, and patient-specific assistive devices are expanding adoption beyond institutional rehabilitation settings. Customization Option Available upon request Frequently Asked Question About This Report Q1. How big is the Therapeutic Robots Market? A1. The global Therapeutic Robots Market is estimated at USD 1.05 billion in 2025 and is projected to reach USD 2.65 billion by 2032. Q2. What is the CAGR for the Therapeutic Robots Market during the forecast period? A2. The Therapeutic Robots Market is expected to grow at a CAGR of 14.4% from 2026 to 2032. Q3. What are the key factors driving the growth of the Therapeutic Robots Market? A3. Growth is driven by rising rehabilitation needs, reimbursement expansion, neurological disorder prevalence, demand for intensive therapy, and adoption of robotic-assisted care. Q4. Which region holds the largest Therapeutic Robots Market share? A4. North America holds the largest share due to strong reimbursement pathways, advanced rehabilitation infrastructure, and higher adoption of medical robotic technologies. Q5. Which product type holds the largest market share in the Therapeutic Robots Market? A5. Rehabilitation Robots hold the largest market share due to their established clinical use in hospitals and rehabilitation centers for gait training and neurological recovery. Sources: Global Rehabilitation Need, Stroke and Spinal Cord Injury Sources World Health Organization – Global Estimates of the Need for Rehabilitation CDC – Stroke Facts and Statistics National Spinal Cord Injury Statistical Center – Traumatic Spinal Cord Injury Facts and Figures at a Glance 2025 Rehabilitation Facility Throughput and Medicare Spending Sources MedPAC – Inpatient Rehabilitation Facility Services MedPAC – Health Care Spending and the Medicare Program: Inpatient Rehabilitation Facility Data Robot-Assisted Rehabilitation Clinical Evidence Sources Electromechanical-Assisted Training for Walking After Stroke Electromechanical-Assisted Training for Walking After Stroke – Full Cochrane Review Medicare Exoskeleton Reimbursement and FDA Clearance Sources CMS – 2023 HCPCS Application Summary for Non-Drug and Non-Biological Items and Services CMS Medicare Contractor – Powered Lower-Extremity Exoskeleton Correct Coding Guidance FDA – ReWalk 7 Personal Exoskeleton 510(k) Clearance Lifeward Revenue, Installed Base and Insurance-Coverage Sources Lifeward – Fourth Quarter and Full-Year 2025 Financial Results Lifeward – First Quarter 2026 Financial Results and Medicare Advantage Coverage Update Myomo Revenue, Device Deliveries and Referral-Network Sources Myomo – Fourth Quarter and Full-Year 2025 Financial and Operating Results Myomo – 2026 Shareholder Letter CYBERDYNE Installed Base and Government Procurement Sources CYBERDYNE – Financial Results and Global HAL Operating-Unit Data for June 2025 CYBERDYNE – Large-Scale HAL Installation at Malaysia’s National Neuro-Robotics and Cybernics Rehabilitation Centre Wandercraft Deployment, Patient-Use and Financing Sources Wandercraft – $75 Million Financing for Global Expansion of AI-Powered Robotics Dementia Burden and Socially Assistive Robot Evidence Sources World Health Organization – Dementia Fact Sheet World Health Organization – World Failing to Address Dementia Challenge World Health Organization – Global Status Report on the Public Health Response to Dementia Intelligent Robot Interventions for People With Dementia: Systematic Review and Meta-Analysis of Randomized Controlled Trials Autism and Paediatric Support Sources CDC – Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years CDC – 2025 Community Report on Autism Table of Contents - Global Therapeutic Robots Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Application, and End User Investment Opportunities in the Therapeutic Robots Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Rehabilitation Robots, Personal Exoskeletons, Myoelectric Orthoses, Socially Assistive Robots, Home-Based Rehabilitation, and High-Intensity Neurological Recovery Programs Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Therapeutic Robots in Rehabilitation, Assistive Mobility, Neurological Recovery, Elderly Care, and Structured Supportive Therapy Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Reimbursement, Regulatory Clearance, Clinical Evidence, and Rehabilitation Infrastructure Factors Role of High-Intensity Rehabilitation, Personal Exoskeleton Coverage, Home Care Expansion, and Neurological Recovery Programs in Market Expansion Therapist Training, Patient Eligibility, Outcome Reporting, Device Utilisation, and Service Support Trends in Therapeutic Robot Deployment Global Therapeutic Robots Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Rehabilitation Robots Personal Exoskeletons & Powered Orthoses Myoelectric Orthoses Socially Assistive Robots Market Analysis by Application: Neurological Rehabilitation Gait & Mobility Training Upper-Limb Rehabilitation Orthopedic Rehabilitation Dementia & Elderly Care Autism & Pediatric Support Market Analysis by End User: Hospitals & Rehabilitation Centers Home Care Settings Specialty Clinics Long-Term Care Facilities Academic & Research Institutes Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Therapeutic Robots Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: United States Canada Mexico Europe Therapeutic Robots Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Therapeutic Robots Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Therapeutic Robots Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Therapeutic Robots Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Ekso Bionics Holdings, Inc. Lifeward Ltd. Myomo, Inc. CYBERDYNE Inc. Wandercraft SAS Hocoma AG Fourier Intelligence Co., Ltd. BIONIK Laboratories Corp. Tyromotion GmbH Reha Technology AG Competitive Landscape and Strategic Insights Benchmarking Based on Regulatory Clearance, Reimbursement Access, Clinical Evidence, Patient Eligibility Support, Device Utilisation, Therapist Training, Service Infrastructure, and Regional Presence Supplier Qualification and Clinical Support Capability Analysis High-Intensity Rehabilitation Robot Positioning Personal Exoskeleton, Powered Orthosis, and Home-Based Rehabilitation Competitiveness Reimbursement Navigation, Outcome Reporting, Maintenance, and Patient Retention Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Application, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Reimbursement Access, Clinical Evidence, and Procurement Risk Analysis Technology Adoption Trends Across Rehabilitation Robots, Personal Exoskeletons & Powered Orthoses, Myoelectric Orthoses, and Socially Assistive Robots List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Application, and End User (2025 vs. 2032) Global Therapeutic Robots Ecosystem and Value Chain Analysis